Bibliographie : Cannabinoïdes et TSA/TED/psychoses infantiles. Dr Christian Sueur, GRECC, mars 2019. (2e version) ARAN A., CASSUTO H., LUBOTZKY : Cannabidiol Based Medical Cannabis in Children with Autism- a Retrospective Feasability Study (P3.318), Neurology Genetics, 2018, 90 (15). http://n.neurology.org/content/90/15_Supplement/P3.318 ARAN A., CASSUTO H., LUBOTZKY A., WATTAD N., HAZAN E. : Brief Report : Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems-A Retrospective Feasability Study, Journal of Autism and Developmental Disorders, 2018 Oct 31. Doi : 10.1007/s10803-018-3808-2 BARCHEL D., STOLAR O., De-HAAN T., ZIV-BARAN T., SABAN N., FUCHS D.O., KOREN G., BERKOVITCH M. : Oral Cannabidiol Use in Children With Auttism Spectrum Disorder to Treat Related Symptoms [...]
Lire la suiteCannabis thérapeutique : les premiers mots historiques d’Edouard Philippe, Premier ministre 6 avril 2019 jeanyvesnau Argent, Douleur, Médecine, médicament, Pharmacie, Polémique, Politique, Pouvoir, Risques (réduction des), santé publique Étiquettes : Agence France Presse https://jeanyvesnau.com/2019/04/06/cannabis-therapeutique-premiers-mots-historiques-dedouard-philippe-premier-ministre/ Bonjour Il l’a dit avec ses mots et ses mots sont ceux d’un Premier ministre. Pour la première fois le chef de gouvernement français s’est exprimé sur le « cannabis thérapeutique ». Et il l’a dit, politique oblige, lors d’un déplacement officiel dans le département périphérique de la Creuse, préfecture Guéret, une seule sous-préfecture : Aubusson. La Creuse, département pauvre, qui nourrit depuis plusieurs mois un projet de culture de cannabis à visée thérapeutique. Un [...]
Lire la suiteKetamine a Panacea for Resistant Depression? Not So Fast, Experts Say Nancy A. Melville April 04, 2019 https://www.medscape.com/viewarticle/911378#vp_3 CHICAGO — Ketamine's rapid antidepressant effects and its recent approval by the US Food and Drug Administration (FDA) has clinicians and patients alike buzzing with excitement. However, for some experts, this excitement only serves to heighten concerns about the many unknowns and potential long-term side effects of the drug, which began its long history as an anesthetic. Here, at the Anxiety and Depression Association of American (ADAA) 2019 Conference, experts debated the drug's merits and potential pitfalls. "These are exciting times and I think ketamine has opened a new era," Carlos [...]
Lire la suiteAntidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: A SPECT Study. Rafael F. Sanchez, F. de Lima Osorio, R.G. Dos Santos, L.R. Macedo, J.P. Maia-de-Oliveira, L. Wichert-Ana, D.B. de Araujo, J. Riba, J.A. Crippa, J.E. Hallak Journal of Clinical Psychopharmacology, 2016, 36, 1, 77-81. doi: 10.1097/JCP.0000000000000436. PMID : 26650973 Abstract Ayahuasca is an Amazonian botanical hallucinogenic brew which contains dimethyltryptamine, a 5-HT2A receptor agonist, and harmine, a monoamine-oxidase A inhibitor. Our group recently reported that ayahuasca administration was associated with fast-acting antidepressive effects in 6 depressive patients. The objective of the present work was to assess the antidepressive potentials of [...]
Lire la suiteClinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol Douglas L. Boggs, Jacques D. Nguyen, Daralyn Morgenson, Michael A. Taffe and Mohini Ranganathan Neuropsychopharmacology. 2018 Jan; 43(1): 142–154. Published online 2017 Oct 18. Prepublished online 2017 Sep 6. doi: 10.1038/npp.2017.209 PMCID: PMC5719112 PMID: 28875990 Abstract The plant Cannabis sativa, commonly called cannabis or marijuana, has been used for its psychotropic and mind-altering side effects for millennia. There has been growing attention in recent years on its potential therapeutic efficacy as municipalities and legislative bodies in the United States, Canada, and other countries grapple with enacting policy to facilitate the use of cannabis or its constituents for [...]
Lire la suiteProspects for the Use of Cannabinoids in Oncology and Palliative Care Practice: A Review of the Evidence. Tomasz DZIERZANOWSKI Cancers (Basel), 2019, 11, 2 Abstract There is an increased interest in the use of cannabinoids in the treatment of symptoms in cancer and palliative care patients. Their multimodal action, in spite of limited efficacy, may make them an attractive alternative, particularly in patients with multiple concomitant symptoms of mild and moderate intensity. There is evidence to indicate cannabis in the treatment of pain, spasticity, seizures, sleep disorders, nausea and vomiting, and Tourette syndrome. Although the effectiveness of cannabinoids is limited, it was confirmed in [...]
Lire la suiteCannabidiol as a suggested candidate for treatment of autism spectrum disorder. POLEG S., GOLUBCHIK P., OFFEN D., WEIZMAN A. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 8, 89, 90-96. doi: 10.1016/j.pnpbp.2018.08.030 Abstract Autism Spectrum Disorder (ASD) is characterized by persistent deficits in social communication, restricted and repetitive patterns of behavior, interests, or activities and often intellectual disabilities. ASD has a number of prevalent co-morbidities, such as sleep disorders, attention deficit/hyperactivity disorder and epilepsy. No effective treatment for the core symptoms of ASD is currently available. There is increasing interest in cannabinoids, especially cannabidiol (CBD), as monotherapy or add-on treatment for the core symptoms and co-morbidities [...]
Lire la suiteCannabidiol provides viable treatment opportunity for multipleneurological pathologies of autism spectrum disorder Bin Gu Global Drugs and Therapeutics, Review article, 2017, 2, 6, 1-4 doi: 10.15761/GDT.1000134 Abstract Autism spectrum disorder (ASD)is a heterogeneous neurodevelopmental disorderaffecting over 1% of the general population. While it is well established that ASD stems from a combination of genetic and environmental factors, there are no defined mechanisms of pathogenesis, rendering curative therapy very difficult to establish. No effective therapy exists for ASD, presenting an urgent clinical need for better control of common core pathologies of ASD regardless of its etiology. Cannabidiol (CBD), a major phytocannabinoid constituent of the cannabis plant, is [...]
Lire la suiteTreatment of Fragile X Syndrome with Cannabidiol: A Case Series Study and Brief Review of the Literature Nicole Tartaglia, Marcel Bonn-Miller, and Randi Hagerman Cannabis and Cannabinoid Research, 2019, 4, 1 https://doi.org/10.1089/can.2018.0053 Abstract Fragile X syndrome (FXS) is an X-linked dominant disorder caused by a mutation in the fragile X mental retardation 1 gene. Cannabidiol (CBD) is an exogenous phytocannabinoid with therapeutic potential for individuals with anxiety, poor sleep, and cognitive deficits, as well as populations with endocannabinoid deficiencies, such as those who suffer from FXS. The objective of this study was to provide a brief narrative review of recent literature on endocannabinoids and FXS and [...]
Lire la suiteRapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer : a randomized controlled trial ROSS S., BOSSIS A., GUSS J., AGIN-LIEBES G., MALONE T., COHEN B., MENNENGA S.E., BELSER A., KALLIONTZI K., BABB J., SU Z., CORBY P., SCHMIDT B.L. Journal of Psychopharmacology, 2016, 30, 12, 1165-1180 DOI: 10.1177/0269881116675512 jop.sagepub.com Abstract Background : Clinically significant anxiety and depression are common in patients with cancer, and are associated with poor psychiatric and medical outcomes. Historical and recent research suggests a role for psilocybin to treat cancer-related anxiety and depression. Methods : In this double-blind, placebo-controlled, crossover trial, 29 patients [...]
Lire la suite